MoonLake Immunotherapeutics (MLTX) Non-Current Assets (2020 - 2026)

MoonLake Immunotherapeutics' Non-Current Assets history runs 7 years deep, the most recent figure standing at $3.7 million for Q1 2026.

• On a quarterly basis, Non-Current Assets fell 25.31% year-over-year to $3.7 million in Q1 2026; TTM through Mar 2026 was $3.7 million, a 25.31% decrease from a year earlier, with the FY2025 full-year figure at $2.7 million, down 24.84% from the prior year.
• Non-Current Assets advanced to $3.7 million in Q1 2026 per MLTX's latest filing, from $2.7 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $115.1 million in Q1 2022 and bottomed at $52679.0 in Q3 2022.
• The 5-year median for Non-Current Assets is $3.6 million (2024), against an average of $10.3 million.
• Across the five-year window, Non-Current Assets sank 99.95% in 2022 and surged 3627.1% in 2023, its largest moves.
• Year by year, Non-Current Assets stood at $331969.0 in 2022, then jumped by 3627.1% to $12.4 million in 2023, then slumped by 70.55% to $3.6 million in 2024, then declined by 24.84% to $2.7 million in 2025, then surged by 36.29% to $3.7 million in 2026.
• Per Business Quant, the three latest MLTX Non-Current Assets figures stand at $3.7 million (Q1 2026), $2.7 million (Q4 2025), and $3.1 million (Q3 2025).